Quizartinib generic drug launch: price reduction forecast in 2025

Quizartinib (Quizartinib), as a new, oral FLT3 inhibitor, has received great attention in the global acute myeloid leukemia (AML) treatment field in recent years, especially in the efficacy of targetingFLT3-ITD mutations. It has made important breakthroughs. However, the price of its original drugs is relatively high, and long-term medication poses a heavy financial burden to most patients, especially those in developing countries. Therefore, the launch progress and price system of generic drugs have become one of the focuses of close attention by patients and medical institutions.

Up to now, generic drugs of Quizartinib have been launched in some overseas markets, especially in generic drug exporting countries such as Laos and Bangladesh. Among them, Lucius Pharmaceutical Factory in Laos has launched the first generic version of Quizartinib. Its ingredients are highly consistent with the original drug, and it is characterized by high cost performance and stable efficacy. It is understood that the common packaging of this version is 14 tablets, with the same specifications as the original drug. The price per box is about RMB 1,000, but it will fluctuate due to exchange rate changes. This price is significantly lower than the original drug’s price of tens of thousands of yuan, providing a practical treatment alternative for many AML patients with limited financial capacity but who need to take long-term medication.

In terms of the efficacy of generic drugs, since generic drugs must pass bioequivalence verification before they can be legally marketed, the efficacy and safety of compliant generic drugs certified by most countries are basically the same as those of original drugs. However, patients still need to be reminded that when choosing generic drugs, patients should purchase them through formal channels to ensure drug quality and reliable sources, and avoid purchasing products without regulatory approval. In addition, the generic version of Quizartinib has not yet been officially launched in mainland China. Patients usually need to obtain it through overseas medical channels such as cross-border e-commerce and purchasing agencies. It is recommended to use it under the guidance of a doctor and pay attention to the country’s import approval status of this type of generic drugs.

Reference materials:https://go.drugbank.com/drugs/DB12874